Literature DB >> 20609777

Non-small cell lung cancer resection in lymphoma patients.

Min P Kim1, Arlene M Correa, Stephen G Swisher, Wayne L Hofstetter, Reza J Mehran, David C Rice, Garrett L Walsh, Jeremy Erasmus, Cesar Moran, Ara A Vaporciyan, Jack A Roth.   

Abstract

BACKGROUND: Lymphoma patients are at an increased risk of developing secondary malignancies, including lung cancer. It is unknown if these patients are at higher risk of dying from pulmonary resection due to lymphoma or if they have reasonable long-term survival.
METHODS: We identified 47 lymphoma patients, seven of which had active lymphoma and forty with a history of lymphoma, who underwent resection for lung cancer between 1998 and 2008. We matched lymphoma patients with lung cancer patients who had no lymphoma based on age, gender, surgery type, comorbidities, stage, and histology. We analyzed differences in the length of hospitalization, morbidity, mortality, and overall and lung cancer specific survival between the lymphoma group and the matched no lymphoma group.
RESULTS: We found no significant difference in length of hospitalization, morbidity, or mortality between the lymphoma and matched no lymphoma group. The lymphoma group's 5-year overall survival rate (35%) was significantly lower than that of the no lymphoma group (67%; p = 0.04). However, the difference in lung cancer-specific survival between the groups was not significant. The cause-of-death analysis revealed that lymphoma patients also died from recurrent lymphoma or myelodysplastic syndrome-acute myeloid leukemia. Multivariate analysis revealed that older age, higher stage, and active lymphoma status were significant adverse predictors of survival.
CONCLUSIONS: There is no significant increase in operative morbidity and mortality for lymphoma patients having pulmonary resection for lung cancer. The survival for lymphoma patients is decreased but still acceptable with no difference in lung cancer-specific survival. Copyright 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20609777     DOI: 10.1016/j.athoracsur.2010.02.114

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

1.  Pathological and clinical features of multiple cancers and lung adenocarcinoma: a multicentre study.

Authors:  Pietro Bertoglio; Luigi Ventura; Vittorio Aprile; Maria Angela Cattoni; Dania Nachira; Filippo Lococo; Maria Rodriguez Perez; Francesco Guerrera; Fabrizio Minervini; Letizia Gnetti; Alessandra Lenzini; Francesca Franzi; Giulia Querzoli; Guido Rindi; Salvatore Bellafiore; Federico Femia; Giuseppe Salvatore Bogina; Diana Bacchin; Peter Kestenholz; Enrico Ruffini; Massimiliano Paci; Stefano Margaritora; Andrea Selenito Imperatori; Marco Lucchi; Luca Ampollini; Alberto Claudio Terzi
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-06-15

2.  A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma.

Authors:  Kentaro Masuhiro; Genju Koh; So Takata; Shingo Nasu; Hiromune Takada; Satomu Morita; Ayako Tanaka; Takayuki Shiroyama; Naoko Morishita; Hidekazu Suzuki; Norio Okamoto; Hiromi Kawasumi; Chihiro Konishi; Tomonori Hirashima
Journal:  Respir Med Case Rep       Date:  2019-05-26

3.  Prognostic factors of lung cancer in lymphoma survivors (the LuCiLyS study).

Authors:  Alfonso Fiorelli; Antonio D'Andrilli; Annalisa Carlucci; Giovanni Vicidomini; Domenico Loizzi; Nicoletta Pia Ardò; Rita Daniela Marasco; Luigi Ventura; Luca Ampollini; Paolo Carbognani; Giovanni Bocchialini; Filippo Lococo; Massimiliano Paci; Teresa Severina Di Stefano; Francesco Ardissone; Matteo Gagliasso; Paolo Mendogni; Lorenzo Rosso; Alessandra Mazzucco; Camilla Vanni; Beatrice Trabalza Marinucci; Rossella Potenza; Alberto Matricardi; Mark Ragusa; Valentina Tassi; Marco Anile; Camilla Poggi; Nicola Serra; Antonello Sica; Mario Nosotti; Francesco Sollitto; Federico Venuta; Erino Angelo Rendina; Francesco Puma; Mario Santini
Journal:  Transl Lung Cancer Res       Date:  2020-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.